Next Generation Sequencing Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Next Generation Sequencing (NGS) Tests Market Report Overview

The Next Generation Sequencing (NGS) tests market size was valued at $41.9 million in 2022. NGS allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. NGS can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

Next Generation Sequencing (NGS) tests Market Outlook 2022-2023 ($ Million)

For more insights on the Next Generation Sequencing (NGS) tests market forecast, download a free sample report

The Next Generation Sequencing (NGS) tests market research report is built to visualize quantitative market trends within in-vitro diagnostics therapeutic areas. Furthermore, the model discusses in detail the impact of COVID-19 on the Next Generation Sequencing (NGS) tests market for the year 2020 and beyond.

Next Generation Sequencing (NGS) tests Market Dynamics

The market for NGS tests will grow across all regions during the forecast period. This growth is being driven by several factors including increasing incidence for lung cancer, breast cancer, ovarian cancer, melanoma and others, greater disease awareness, improved accessibility to NGSs in emerging economies, and technological advancements.

NGS use as the industry moves away from the established model of testing for single mutations only. Adoption of Comprehensive Genetic Profiling of dozens to hundreds of genes via NGS-based techniques will supplant traditional single-mutation tests in the long term. In general, market growth might be affected by challenges in routine practice including the cost of molecular profiling, social inequalities that limit access to tests, the widespread molecular tumor boards, and access to clinical trials for patients with uncommon mutations.

For additional Next Generation Sequencing (NGS) tests market dynamics, download a free sample report

Next Generation Sequencing (NGS) tests Market Segmentation by Regions

The key regions in the Next Generation Sequencing (NGS) tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2022, Europe dominated the NGS tests market share. The growth of the NGS test market will be driven by improvements in technologies and decreased costs. Despite problems associated with NGS, including the lack of central regulation, standardization of the platforms used, interpretation, and validation of findings, the technique holds much promise for the future.

Next Generation Sequencing (NGS) tests Market Analysis by Regions, 2022 (%)

For more regional insights in the Next Generation Sequencing (NGS) tests market, download a free sample report

Next Generation Sequencing (NGS) tests Market – Competitive Landscape

The key companies in the Next Generation Sequencing (NGS) tests market are Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Agilent Technologies Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Roche Diagnostics International Ltd + Foundation Medicine Inc, and Burning Rock Biotech Ltd among others. In 2022, Otsuka Pharmaceutical Co Ltd accounted for the highest Next Generation Sequencing (NGS) tests market share and value.

Next Generation Sequencing (NGS) tests Market Analysis by Companies, 2022 (%)

For more company insights into the Next Generation Sequencing (NGS) tests market, download a free sample report

Segments Covered in this Report

Next Generation Sequencing (NGS) tests Regional Outlook ($ Million, 2015-2033)

• Asia-Pacific
• Europe
• Middle East and Africa
• North America
• South and Central America

Key Inclusions of the market model are –

Currently marketed Next Generation Sequencing (NGS) tests market and evolving competitive landscape –

• Insightful review of the key industry trends.
• Annualized total Next Generation Sequencing (NGS) tests market revenue by segment and market outlooks from 2015-2033.
• Market-level data on units, average selling prices, and market values.

Global, Regional and Country level market specific insights –

• Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for Next Generation Sequencing (NGS) tests market.
• Competitive dynamics insights and trends provided for Next Generation Sequencing (NGS) tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Agilent Technologies Inc, New England Biolabs Inc, Takara Bio Inc, Amoy Diagnostics Co Ltd, Burning Rock Biotech Ltd and others.

Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for

• CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to –

• Understand the impact of COVID-19 on Next Generation Sequencing (NGS) tests.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Next Generation Sequencing (NGS) tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.